Abstract:Since the advent of the twentieth century, several severe virus outbreaks have occurred—H1N1 (1918), H2N2 (1957), H3N2 (1968), H1N1 (2009) and recently COVID-19 (2019)—all of which have posed serious challenges to public health. Therefore, rapid identification of efficacious antiviral medications is of ongoing paramount importance in combating such outbreaks. Due to the long cycle of drug development, not only in the development of a “safe” medication but also in mandated and extensive (pre)clinical trials before a drug can be safely licensed for use, it is difficult to access effective and safe novel antivirals. This is of particular importance in addressing infectious disease in appropriately short period of time to limit stress to ever more interlinked societal infrastructures; including interruptions to economic activity, supply routes as well as the immediate impact on health care. Screening approved drugs or drug candidates for antiviral activity to address emergent diseases (i.e. repurposing) provides an elegant and effective strategy to circumvent this problem. As such treatments (in the main) have already received approval for their use in humans, many of their limitations and contraindications are well known, although efficacy against new diseases must be shown in appropriate laboratory trials and clinical studies. A clear in this approach in the case of antivirals is the “relative” simplicity and a high degree of conservation of the molecular mechanisms that support viral replication—which improves the chances for a functional antiviral to inhibit replication in a related viral species. However, recent experiences have shown that while repurposing has the potential to identify such cases, great care must be taken to ensure a rigourous scientific underpinning for repurposing proposals. Here, we present a brief explanation of drug repurposing and its approaches, followed by an overview of recent viral outbreaks and associated drug development. We show how drug repurposing and combination approaches have been used in viral infectious diseases, highlighting successful cases. Special emphasis has been placed on the recent COVID-19 outbreak, and its molecular mechanisms and the role repurposing can/has play(ed) in the discovery of a treatment.

Drug repurposing: a systematic review on root causes, barriers and facilitators

Drug Repurposing: An Effective Tool in Modern Drug Discovery

Drug repurposing: progress, challenges and recommendations

Drug Repurposing in the Chemotherapy of Infectious Diseases

A Comprehensive Review of Drug Repurposing Strategies against Known Drug Targets of COVID-19

Are we there yet? Analyzing scientific research related to COVID-19 drug repurposing

Repurposing of Drugs: Updates and New Perspectives

The dark side of drug repurposing. From clinical trial challenges to antimicrobial resistance: analysis based on three major fields

A review on drug repurposing in COVID-19: from antiviral drugs to herbal alternatives

Drug Repurposing: A Leading Strategy for New Threats and Targets

Drug repositioning: Progress and challenges in drug discovery for various diseases

Repurposing – second life for drugs

Revitalizing Cancer Treatment: Exploring the Role of Drug Repurposing

New government drug repurposing programs: Opportunities and uncertainties

Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government

Drug Repurposing Techniques in Viral Diseases

Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates

Drug Repurposing Against Coronavirus Disease 2019 (COVID-19): A Review

Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight

The landscape of the methodology in drug repurposing using human genomic data: a systematic review

Drug Repurposing: Far Beyond New Targets for Old Drugs